Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Director Edward M. Md Kaye sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $41.00, for a total transaction of $410,000.00. Following the completion of the transaction, the director now owns 62,471 shares of the company’s stock, valued at $2,561,311. The sale was disclosed in a legal filing with the SEC, which is available at this link.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) traded down 0.46% during midday trading on Friday, hitting $36.70. 1,272,093 shares of the stock were exchanged. The company’s 50 day moving average is $37.48 and its 200-day moving average is $33.08. Sarepta Therapeutics, Inc. has a 1-year low of $24.96 and a 1-year high of $63.73. The stock’s market cap is $2.36 billion.
Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Wednesday, July 19th. The biotechnology company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.46. The company had revenue of $35.01 million during the quarter, compared to the consensus estimate of $22.52 million. The business’s revenue was up 350000.0% on a year-over-year basis. During the same quarter last year, the firm earned ($1.19) EPS. On average, analysts expect that Sarepta Therapeutics, Inc. will post ($1.16) earnings per share for the current year.
SRPT has been the subject of several analyst reports. Piper Jaffray Companies set a $43.00 target price on shares of Sarepta Therapeutics and gave the company a “buy” rating in a research report on Thursday, May 18th. Vetr cut shares of Sarepta Therapeutics from a “strong-buy” rating to a “buy” rating and set a $36.86 target price for the company. in a research report on Monday, May 15th. SunTrust Banks, Inc. restated a “buy” rating and issued a $45.00 target price on shares of Sarepta Therapeutics in a research report on Tuesday, May 2nd. Cowen and Company reaffirmed a “buy” rating on shares of Sarepta Therapeutics in a report on Friday, April 28th. Finally, Nomura reaffirmed a “buy” rating and set a $84.00 price target on shares of Sarepta Therapeutics in a report on Tuesday, May 23rd. Eight analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $61.28.
A number of hedge funds have recently added to or reduced their stakes in the stock. Prentiss Smith & Co. Inc. boosted its stake in Sarepta Therapeutics by 772.2% in the second quarter. Prentiss Smith & Co. Inc. now owns 3,576 shares of the biotechnology company’s stock valued at $121,000 after buying an additional 3,166 shares during the period. Ameritas Investment Partners Inc. bought a new stake in Sarepta Therapeutics during the first quarter valued at $127,000. PNC Financial Services Group Inc. boosted its stake in Sarepta Therapeutics by 150.1% in the first quarter. PNC Financial Services Group Inc. now owns 4,666 shares of the biotechnology company’s stock valued at $138,000 after buying an additional 2,800 shares during the period. Cubist Systematic Strategies LLC boosted its stake in Sarepta Therapeutics by 116.4% in the second quarter. Cubist Systematic Strategies LLC now owns 4,600 shares of the biotechnology company’s stock valued at $155,000 after buying an additional 2,474 shares during the period. Finally, Edge Wealth Management LLC bought a new stake in Sarepta Therapeutics during the second quarter valued at $175,000. Institutional investors and hedge funds own 63.11% of the company’s stock.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.